Erratum: Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma (Targeted Oncology (2012) 7 (199-210) DOI: 10.1007/s11523-012-0227-8);Targeting ALK: A promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma

Targeted Oncology

Volumn 7, Issue 3, 2012, Pages 199-210

  La Madrid, Andres Morales ^a   Campbell, Nicholas ^a   Smith, Sonali ^a   Cohn, Susan L ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

ALK; Neuroblastoma; Non Hodgkin's lymphoma; Non small cell lungcancer

Indexed keywords

3,5 DIAMINO 1,2,4 TRIAZOLE BENZYLUREA; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; ASP 3026; BRENTUXIMAB VEDOTIN; CEP 28122; CH 5424802; CRIZOTINIB; CRL 151104A; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GANETESPIB; GRANZYME B; IPI 204; JANUS KINASE; LDK 378; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PERFORIN; PF 03446962; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE B; RETASPIMYCIN; STAT PROTEIN; TAE 684; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALK GENE; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; DRUG APPROVAL; DRUG PENETRATION; DRUG RESISTANCE; DRUG TARGETING; EML4 GENE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EVENT FREE SURVIVAL; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENE TRANSLOCATION; GENETIC HETEROGENEITY; HUMAN; HYPOGONADISM; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; T CELL LYMPHOMA; TUMOR XENOGRAFT; VISUAL DISORDER;

EID: 84872277710     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0291-8     Document Type: Erratum

References (115)

1. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151): 1281-1284
2. Azarova AM, Gautam G, George RE (2011) Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 21(4): 267-275
3. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q et al (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9(3): 331-356
4. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430(3): 425-437
5. Tartari CJ, Gunby RH, Coluccia AM, Sottocornola R, Cimbro B, Scapozza L et al (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 283(7): 3743-3750
6. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4): 439-449
7. The human protein atlas. Electronic citation 2012 Available from: www.proteinatlas.org
8. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C et al (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276 (20): 16772-16779
9. Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A (2002) Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem 277 (16): 14153-14158
10. Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A et al (2002) Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21(38): 5823-5834
11. Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C et al (2006) Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26(16): 6209-6222
12. Catalog of somatic mutations in cancer. Electronic citation 2012 Available from: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic? action0gene&ln0ALK
13. Catlog of somatic mutations in cancer. Electronic citation 2012 Available from: http://www.sanger.ac.uk/perl/genetics/CGP/cosmic? action0bygene& ln0ALK&start01&end01621&coords0AA: A.A.
14. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61 (4): 212-236
15. Lung cancer - National Cancer Institute. Electronic citation 2012 Available from: http://www.cancer.gov/cancertopics/types/lung
16. Cancer of the lungs and bronchus - SEER Stat Fact Sheets. Electronic citation 2012 Available from: http://seer.cancer.gov/statfacts/html/lungb.html
17. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24): 2542-2550
18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al. (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21): 3543-3551
19. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153): 561-566
20. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27(26): 4232-4235
21. Sasaki T, Rodig SJ, Chirieac LR, Janne PA (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46(10): 1773-1780
22. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105(50): 19893-19897
23. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol 27(26): 4247-4253
24. Shaw AT et al. Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer. J Clin Oncol 28. 4-3-2010. Ref Type: Abstract
25. Martinez P et al. ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and inmunohistochemistry diagnostic methods, prevalence, and clinical outcomes. J Clin Oncol 29. 6-1-2011. Ref Type: Abstract
26. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10): 958-967
27. Kim ES, Salgia R (2009) MET pathway as a therapeutic target. J Thorac Oncol 4(4): 444-447
28. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in nonsmall- cell lung cancer. N Engl J Med 363(18): 1693-1703
29. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11): 1004-1012
30. Shaw AT et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol 29. 3-12-2011. Ref Type: Abstract
31. Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak- Vassiliades K, Oton AB, Doebele RC et al. (2012) Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic non-small cell lung cancer. Cancer. doi: 10.1002/cncr.27450
32. Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17(23): 7394-7401
33. A clinical trial testing the efficacy of crizotinib versus standard chemotherapy pemetrexed plus cisplatin or carboplatin in patients with ALK positive non-squamous cancer of the lung. Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01154140? term0alk+pemetrexed&rank02
34. Swerdlow S, Campo E, Harris NL et al. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. World Health Organization, Lyon
35. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25): 4124-4130
36. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al (2008) ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111 (12): 5496-5504
37. Lamant L, de Reynies A, Duplantier MM, Rickman DS, Sabourdy F, Giuriato S et al (2007) Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 109 (5): 2156-2164
38. Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B et al (2008) Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 140(5): 516-526
39. Thompson MA, Stumph J, Henrickson SE, Rosenwald A, Wang Q, Olson S et al (2005) Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinasenegative anaplastic large cell lymphomas. Hum Pathol 36 (5): 494-504
40. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T, TakeshitaMet al (1995) Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 86(5): 1954-1960
41. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9(6): 1567-1574
42. Amin HM, Lai R (2007) Pathobiology of ALK+ anaplastic largecell lymphoma. Blood 110(7): 2259-2267
43. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8(1): 11-23
44. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY et al (1997) Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90 (8): 2901-2910
45. Wasik MA, Zhang Q, Marzec M, Kasprzycka M, Wang HY, Liu X (2009) Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Semin Oncol 36(2 Suppl 1): S27-S35
46. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R et al (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11(6): 623-629
47. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M et al (2002) Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (7): 1038-1047
48. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N et al (2005) Inhibition of ALK enzymatic activity in Tcell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85(12): 1544-1554
49. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA (2005) STAT3- and DNA methyltransferase 1- mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A 102(19): 6948-6953
50. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA (2006) STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 108(3): 1058-1064
51. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L et al (2001) Role of phosphatidylinositol 3- kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61(5): 2194-2199
52. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L et al (2006) Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66(13): 6589-6597
53. Marzec M, Kasprzycka M, Liu X, El-SalemM, Halasa K, Raghunath PN et al (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26(38): 5606-5614
54. McDonnell SR, Hwang SR, Basrur V, Conlon KP, Fermin D, Wey E et al. (2011) NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis. Oncogene. doi: 10.1038/onc.2011.542
55. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al (2010) Treatment and prognosis of mature T-cell and NKcell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18): 3418-3425
56. Skarbnik AP, Smith MR (2012) Brentuximab vedotin in anaplastic large cell lymphoma. Expert Opin Biol Ther 12(5): 633-639
57. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19): 1812-1821
58. Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D et al (2009) Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 52(3): 335-339
59. Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364(8): 775-776
60. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P et al (1997) A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 89 (5): 1483-1490
61. Laurent C, Do C, Gascoyne RD, Lamant L, Ysebaert L, Laurent G et al (2009) Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 27(25): 4211-4216
62. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink HK et al (2003) ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 102(7): 2568-2573
63. De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A et al. (2003) ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102(7): 2638-2641
64. Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C et al. (2011) Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One 6(4): e18436
65. Beltran B, Castillo J, Salas R, Quinones P, Morales D, Hurtado F et al (2009) ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol 2: 11
66. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579): 2106-2120
67. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (4653): 1121-1124
68. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313(18): 1111-1116
69. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41(11 Pt 1): 4678-4686
70. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C et al (2007) Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2(2): e255
71. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215): 930-935
72. Ogawa S, Takita J, Sanada M, Hayashi Y (2011) Oncogenic mutations of ALK in neuroblastoma. Cancer Sci 102(2): 302-308
73. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret Vet al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455 (7215): 967-970
74. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215): 971-974
75. George RE, Sanda T, Hanna M, Frohling S, Luther W, Zhang J et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455(7215): 975-978
76. Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS et al. (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3(108): 108ra114
77. De BS, De PK, Kumps C, Zabrocki P, Porcu M, Westerhout EM et al (2010) Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16(17): 4353-4362
78. Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthur A, Ackermann S et al (2011) High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 17(15): 5082-5092
79. Passoni L, Longo L, Collini P, Coluccia AM, Bozzi F, Podda Met al (2009) Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69(18): 7338-7346
80. Weiser D, Laudenslager M, Rappaport E, Carpenter E, Attiyeh EF, Diskin S et al. Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. J Clin Oncol 29. 6-6-2011. Ref Type: Abstract
81. Crizotinib in treating young patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT00939770?term0NCT00939770&rank01
82. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5): 1472-1482
83. Camidge DR, Doebele RC (2012) Treating ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol 9: 268-277
84. Lovly CM, Pao W (2012) Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 4 (120): 120ps2
85. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B et al. (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4 (120): 120ra17
86. Deng X, Wang J, Zhang J, Sim T, Kim ND, Sasaki T et al (2011) Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors. ACS Med Chem Lett 2(5): 379-384
87. A first in patient, study of investigational drug PF-03446962 in patients with advanced solid tumors. Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT00557856? term0PF-03446962&rank02
88. A dose finding study with oral LDK378 in patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK). Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/ NCT01283516?term0ldk +378&rank01
89. Study of an investigational drug, ASP3026, in patients with solid tumors. Electronic citation 2012 Available from: http://clinicaltrials. gov/ct2/show/NCT01401504?term0asp3026&rank01
90. EML4-ALK mutation: consider Xalkori. Electronic citation 2012 Available from: http://www.collabrx.com/lung/lookup?subtype- 3.1no-others-3.1
91. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R et al (2012) A novel classification of lung cancer into molecular subtypes. PLoS One 7(2): e31906
92. A phase 1/2 study of the oral ALK/EGFR inhibitor AP26113. Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01449461? term0ap26113&rank01
93. Carpenter EHE, Chow A, Christensen J, Maris J, Mosse Y. Mechanisms of resistance to small molecule inhibition of anaplastic lymphoma kinase in human neuroblastoma. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research Abstract 742. 4-1-2011. Ref Type: Abstract
94. Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M et al (2011) Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther 19(6): 1131-1140
95. Bonvini P, Gastaldi T, Falini B, Rosolen A (2002) Nucleophosmin- anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90- client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res 62(5): 1559-1566
96. Crizotinib and STA-9090 in ALK positive lung cancers. Electronic citation 2012 Available from: http://clinicaltrials.gov/ct2/show/NCT01579994? term0STA9090&rank09
97. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R et al (2010) Activity of IPI-504, a novel heatshock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28(33): 4953-4960
98. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D et al (2010) Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70(23): 9827-9836
99. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M et al (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3 (1): 13-17
100. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N et al (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22(4): 508-515
101. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14 (13): 4275-4283
102. Shinmura K, Kageyama S, Tao H, Bunai T, Suzuki M, Kamo T et al (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61(2): 163-169
103. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D et al (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174(2): 661-670
104. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wildtype EGFR and KRAS. Cancer 115(8): 1723-1733
105. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALKpositive lung cancer. Clin Cancer Res 15(9): 3143-3149
106. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68 (13): 4971-4976
107. Takeuchi K, Choi YL, SodaM, Inamura K, Togashi Y, Hatano S et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14(20): 6618-6624
108. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 98(9): 1536-1539
109. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ et al (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10(3): 298-302
110. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E et al (2010) Clinicopathologic features of non-smallcell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17(3): 889-897
111. Wong DW, Leung EL,Wong SK, Tin VP, Sihoe AD, Cheng LC et al (2011) A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 117(12): 2709-2718
112. Hernandez L, Bea S, Bellosillo B, Pinyol M, Falini B, Carbone A et al (2002) Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 160(4): 1487-1494
113. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14(9): 1533-1559
114. Caren H, Abel F, Kogner P, Martinsson T (2008) High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416 (2): 153-159
115. Murugan AK, Xing M (2011) Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res 71 (13): 4403-4411